HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF): TREATMENT OPTIONS AND PATIENT OUTCOMES DOI Creative Commons

Aisha Alyassi,

Anitha Panneerselvam,

Azka Arshad

et al.

Journal of Population Therapeutics and Clinical Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 14, 2024

Hu et al specified that HFpEF is undoubtedly a major as well diverse structural type of heart failure affecting nearly half the new patients identified globally. Compared to HFrEF, similar situation observed in where underlying mechanisms disease are broader and it extremely difficult manage disorder. This study found that, despite optimal medical therapy, with had marked symptom burden, high hospitalization rate, reduced health-related quality life, indicating need for better therapeutic management strategies. The systematic review current treatment diagnosed will focus on effectiveness treatments. In this regard, aims determine knowledge gaps evident within available literature proposals subsequent clinical investigations. search incorporated databases PubMed, Cochrane Library, Embase, Web Science, adhering PRISMA protocol. Article inclusion was guided by specific conditions namely, trials, observation studies, systemic reviews comparing treatments HFpEF. Data extraction assessment were performed using standard tools made very reliable valid. Overall, 45 closed trials met eligibility criterion. Previous pharmacological including ARNIs, SGLT2i MRAs modest effect decreasing CV hospitalizations but neutral small all-cause mortality. Frequent devices such lifestyle changes exercise protocols seen upgrade functional ability besides increasing life However, none these highly effective, always necessitating combination individualized approach. conclusion, therapy presents itself several options have shown promising results complexity disorder due wide divergence its presentation. These suggest pharmacotherapy should be further complemented modifications improve functioning patients. More work has done precisely define individual approaches addressing heterogeneous pathophysiology set clear recommendations.

Language: Английский

Nutritional Strategies for Battling Obesity-Linked Liver Disease: the Role of Medical Nutritional Therapy in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management DOI Creative Commons
Daniel Simancas‐Racines, Giuseppe Annunziata, Ludovica Verde

et al.

Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: Jan. 11, 2025

This narrative review explores the role of Medical Nutritional Therapy (MNT) in managing Metabolic-Associated Steatotic Liver Disease (MASLD), previously known as nonalcoholic fatty liver disease. It aims to examine effectiveness specific nutritional strategies preventing and treating this obesity-linked Emerging evidence underscores benefits Mediterranean diet, low-carbohydrate diets, intermittent fasting reducing fat, improving insulin sensitivity, mitigating inflammation. Supplementing with vitamin E, omega-3 acids, silymarin can potentially reduce fibrosis promote health. MNT is a key intervention for MASLD management, emphasizing dietary patterns, caloric restriction, nutraceutical supplementation. Integrating these lifestyle modifications, including regular physical activity, offers comprehensive approach metabolic outcomes patients MASLD. Further research needed refine personalize therapeutic interventions.

Language: Английский

Citations

7
Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions DOI Open Access
M H Miran Beygi, Salma Ahi, Samaneh Zolghadri

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(14), P. 2220 - 2220

Published: July 11, 2024

Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting that affects millions of people around the world. It best identified with hepatic fat build-up ultimately leads to inflammation and damage. The classification nomenclature NAFLD have long been controversial topic, until 2020 when group international experts recommended substituting MAFLD (metabolic dysfunction-associated FLD). was then terminologically complemented in 2023 by altering it MASLD, i.e., metabolic steatotic (MASLD). Both MASLD terminologies comprise element disorder, as they offer diagnostic benchmarks are embedded risk factors underlie disease. (as multisystemic disease) provides comprehensive definition includes larger population patients who at morbidity mortality, well adverse cardiovascular diabetes outcomes. highlights risks lean or normal weight individuals, factor has not accentuated discussed previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, exercise therapies extensively studied MASLD. Nutrition plays vital role managing both conditions, where centralizing on diet rich whole vegetables, fruits, foods, healthy fats, proteins, specific nutrients (e.g., omega-3 acids fibers) can improve insulin resistance reduce inflammation. Thus, essential understand nutrition these conditions work develop an individualized plan for optimal health. This review discusses prevention strategies NAFLD/MAFLD/MASLD management, particular attention correction.

Language: Английский

Citations

14
Leisure-Time Physical Activity in Subjects with Metabolic-Dysfunction-Associated Steatotic Liver Disease: An All-Cause Mortality Study DOI Open Access

Ritanna Curci,

Caterina Bonfiglio, Isabella Franco

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(13), P. 3772 - 3772

Published: June 27, 2024

Background: Metabolic-dysfunction-associated steatotic liver disease (MASLD) affects 30% of adults worldwide and is associated with obesity cardiovascular risk factors. If left untreated, it can progress to severe disease. Lifestyle changes such as physical activity weight loss help reduce the severity mortality. This study estimated impact MASLD leisure-time (LTPA) on mortality examined how gender mediates this effect in a Southern Italian population. Methods: work population-based prospective cohort inhabitants Castellana Grotte (>30 years old) Italy, which began 1985. Participants provided general health information, underwent anthropometric measurements ultrasonography, completed validated questionnaire their food intake LTPA. The vital status was tracked through local municipalities Results: In total, 1826 participants (39% MASLD) were enrolled study, drawn from 2970 eligible subjects; mean age 51.91 (±14.76) 56.2% men. Subjects who practiced low LTPA had significantly higher death than those did not have high addition, subjects about 19% less likely survive 82 years. As regards gender, both men women showed significant death, but women. Conclusions: presence MASLD, especially women, increases all causes. plays key role reduces these individuals.

Language: Английский

Citations

4
Fasting Mimicking Diet for Metabolic Syndrome: A Narrative Review of Human Studies DOI Creative Commons
Alina Delia Popa, Andreea Gherasim, Laura Mihalache

et al.

Metabolites, Journal Year: 2025, Volume and Issue: 15(3), P. 150 - 150

Published: Feb. 23, 2025

Metabolic syndrome (MetS) is an association of risk factors that share insulin resistance (IR), exerting a super cumulative effect on the developing cardiometabolic diseases. Lifestyle optimization key element in prevention and non-pharmacological therapy MetS. Certain studies have concluded some dietary patterns could be more beneficial as adjunctive treatment for Fasting mimicking diet (FMD) form periodic fasting which caloric intake restricted 5 days each month. It has been studied its effects not only patients with neoplasia neurodegenerative diseases but also IR metabolism. In this narrative review, FMD MetS were analyzed, focusing impact metabolic components summarizing findings from human studies. demonstrated by reducing BMI waist circumference, preserving lean mass, improving profile. Moreover, individuals higher or greater number appear to derive benefits intervention. However, limitations such high dropout rates, small sample sizes, methodological constraints restrict generalizability current findings. Further large-scale are needed confirm these establish viable strategy managing

Language: Английский

Citations

0
Consensus Guidelines for the Diagnosis and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Adult Asian Indians with Type 2 Diabetes DOI
Anoop Misra, Ashish Kumar, Mohammad Shafi Kuchay

et al.

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Journal Year: 2025, Volume and Issue: 19(3), P. 103209 - 103209

Published: March 1, 2025

Language: Английский

Citations

0
The Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease DOI Open Access
Diren Beyoğlu, Jeffrey R. Idle

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 2882 - 2882

Published: March 22, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition wherein excessive fat accumulates in the liver, leading to inflammation and potential damage. In this narrative review, we evaluate tissue microbiota, how they arise their constituent microbes, role of intestinal hepatic microbiota MASLD. The history bacteriophages (phages) occurrence part causation MASLD, conversely, "phage therapy" for antibiotic resistance, obesity, are all described. metabolism bile acids dietary tryptophan histidine defined, together with impacts individual metabolites on MASLD pathogenesis. Both periodontitis dysbiosis may cause microorganisms involved these processes discussed. Novel treatment opportunities involving exist include fecal transplantation, probiotics, prebiotics, synbiotics, supplements, intermittent fasting, phages or holins endolysins. Although FDA yet approve phage therapy clinical use, there multiple FDA-approved trials, represent new horizon future

Language: Английский

Citations

0
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease DOI
Bryan Adrian Priego‐Parra, Rocío Gallego‐Durán, Berenice M Román-Calleja

et al.

Trends in Endocrinology and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Ernährung und körperliches Training bei Lebererkrankungen DOI

Thomas-Matthias Scherzer,

Bettina Knabl,

Bernard Mehl

et al.

Journal für Gastroenterologische und Hepatologische Erkrankungen, Journal Year: 2025, Volume and Issue: unknown

Published: April 16, 2025

Citations

0
Potential of Chlorogenic Acid in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Animal Studies and Clinical Trials—A Narrative Review DOI Creative Commons

Agnieszka Ziółkiewicz,

Przemysław Niziński, Jakub Soja

et al.

Metabolites, Journal Year: 2024, Volume and Issue: 14(6), P. 346 - 346

Published: June 20, 2024

Chlorogenic acid (CGA) is a natural polyphenol found in coffee, tea, vegetables, and fruits. It exhibits strong antioxidant activity possesses several other biological properties, including anti-inflammatory effects, antimicrobial activity, insulin-sensitizing properties. Moreover, it may improve lipid glucose metabolism. This review summarizes the available information on therapeutic effect of CGA metabolic dysfunction-associated steatotic liver disease (MASLD). As literature search engine, browsers PubMed, Scopus, Web Science databases, ClinicalTrials.gov register were used. Animal trials clinical studies suggest that has promising potential treating MASLD hepatic steatosis. Its mechanisms action include antioxidant, anti-inflammatory, anti-apoptotic effects via activation Nrf2 signaling pathway inhibition TLR4/NF-κB cascade. Furthermore, alleviation by also involves important molecules such as AMPK physiological processes intestinal barrier gut microbiota. Nevertheless, specific target cell key molecule to which directed remain unidentified require further study.

Language: Английский

Citations

3
Distinct biophysiological effects of Ramadan fasting and traditional intermittent fasting on markers of body fat storage. A real-life study DOI
Mohamad Khalil,

Hala Abdallah,

Nour Jaber

et al.

European Journal of Internal Medicine, Journal Year: 2024, Volume and Issue: 129, P. 111 - 120

Published: Aug. 26, 2024

Language: Английский

Citations

3